CX3CL1 as a Radioligand Therapy Target
CX3CL1, C-X3-C motif chemokine ligand 1, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, CX3CL1 staining is highest in colorectal cancer (100% of samples positive), head and neck cancer (100% of samples positive) and ovarian cancer (100% of samples positive). Clinical status: Clinical-stage (up to phase 2, any modality).
Is CX3CL1 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in colorectal cancer, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ✅ Clinical precedent: Clinical-stage (up to phase 2, any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
CX3CL1 expression in cancer
Protein expression of CX3CL1 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Colorectal Cancer | 1.00 | High | 100% |
| Head and Neck Cancer | 1.00 | High | 100% |
| Ovarian Cancer | 1.00 | High | 100% |
| Lymphoma | 1.00 | High | 100% |
| Melanoma | 1.00 | High | 100% |
| Thyroid Cancer | 1.00 | High | 100% |
| Lung Cancer | 1.00 | High | 100% |
| Prostate Cancer | 1.00 | High | 100% |
| Testicular Cancer | 1.00 | High | 100% |
| Endometrial Cancer | 1.00 | High | 100% |
| Liver Cancer | 0.97 | High | 100% |
| Breast Cancer | 0.97 | High | 100% |
| Cervical Cancer | 0.97 | High | 100% |
| Pancreatic Cancer | 0.96 | High | 100% |
| Bladder Cancer | 0.94 | High | 100% |
| Gastric Cancer | 0.94 | High | 100% |
| Neuroendocrine Tumors | 0.92 | High | 100% |
| Skin Cancer | 0.89 | High | 100% |
| Glioma | 0.83 | High | 100% |
| Kidney Cancer | 0.67 | High | 91% |
Is CX3CL1 internalized?
Nuclens has not yet extracted internalization evidence for CX3CL1. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
CX3CL1 clinical trials
Clinical-stage (up to phase 2, any modality). Nuclens hasn't indexed trials for CX3CL1 yet. Search ClinicalTrials.gov for CX3CL1 trials.
CX3CL1 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See CX3CL1 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
CX3CL1 gene essentiality (DepMap)
CRISPR knockout effect across 1256 cancer cell lines: 0.07 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related colorectal cancer radioligand targets
c-MET (MET) · HER3 (ERBB3) · FAP · EGFR · CEA (CEACAM5) · EPCAM · SSTR2 · STEAP2
See all radioligand therapy targets in colorectal cancer.
See how CX3CL1 ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.